Rapport d’analyse de la taille, de la part et des tendances du marché mondial de la brucellose – Aperçu et prévisions de l’industrie jusqu’en 2031

Analyse du marché de la brucellose

Le marché de la brucellose est en pleine expansion en raison de l'incidence croissante de la brucellose, en particulier dans les régions dépendantes de l'élevage. Les développements récents comprennent des avancées dans les technologies de diagnostic, telles que les tests PCR et les analyses sérologiques, permettant une détection précoce et précise. Les programmes de vaccination du bétail atteint de brucellose ont également connu des améliorations, de nouveaux vaccins offrant une meilleure efficacité. L'analyse du marché indique une demande croissante de kits de diagnostic, de vaccins et de traitements, en particulier en Asie-Pacifique, en Amérique latine et en Afrique, où la charge de morbidité est plus élevée. Les initiatives gouvernementales, les collaborations internationales et l'augmentation du financement de la R&D contribuent à stimuler la croissance du marché. Cependant, des défis tels que la sous-déclaration, le manque de sensibilisation dans les régions rurales et le besoin de traitements plus efficaces persistent. Les innovations en cours et les partenariats stratégiques devraient stimuler davantage l'expansion du marché.

Taille du marché de la brucellose

Français La taille du marché mondial de la brucellose a été évaluée à 276,43 millions USD en 2023 et devrait atteindre 393,11 millions USD d'ici 2031, avec un TCAC de 4,50 % au cours de la période de prévision de 2024 à 2031. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Tendances du marché de la brucellose

« Augmentation de la prévalence de cette maladie zoonotique »

Le marché de la brucellose connaît une croissance en raison de la prévalence croissante de cette maladie zoonotique, en particulier dans les régions dépendantes de l'élevage. La brucellose, causée par la bactérie Brucella, se propage par les produits laitiers crus, le contact avec des animaux infectés et l'air contaminé. Les innovations en matière de diagnostic, telles que les tests PCR et ELISA, ont amélioré la détection précoce, tandis que de nouveaux vaccins pour le bétail plus efficaces sont en cours de développement pour prévenir la transmission. Une tendance clé est l'accent croissant mis sur les mesures préventives, notamment les campagnes de vaccination et l'amélioration des soins vétérinaires dans les zones à haut risque. Le marché est stimulé par une sensibilisation croissante, une amélioration des infrastructures de santé et des initiatives soutenues par les gouvernements, en particulier dans les pays en développement.

Portée du rapport et segmentation du marché de la brucellose 

Définition du marché de la brucellose

La brucellose est une infection zoonotique causée par la bactérie Brucella, transmise principalement à l'homme par contact direct avec des animaux infectés, par la consommation de produits laitiers non pasteurisés ou par l'inhalation de particules contaminées. Elle provoque des symptômes pseudo-grippaux, notamment de la fièvre, des douleurs articulaires et de la fatigue, et peut entraîner des problèmes de santé chroniques si elle n'est pas traitée. Elle touche principalement le bétail, ce qui en fait un problème de santé publique majeur.

Dynamique du marché de la brucellose

Conducteurs

• Augmentation de l'incidence des programmes de vaccination

The development and implementation of effective vaccines for livestock are crucial market drivers for brucellosis prevention efforts. Vaccination plays a vital role in controlling the spread of the disease, as it significantly reduces the incidence of brucellosis in animal populations. By immunizing livestock, the risk of transmission to humans through contaminated milk or direct contact is greatly diminished. Enhanced vaccine formulations, offering improved efficacy and safety profiles, are being developed and adopted globally. This proactive approach safeguards public health and protects livestock productivity, ensuring food security and economic stability for farmers, thereby increasing the overall demand for vaccines in the market.

• Increased International Trade and Travel

The increased international trade of livestock and animal products significantly heightens the risk of brucellosis transmission across borders, acting as a critical market driver for enhanced control measures. As countries engage in global commerce, the movement of infected animals and contaminated products can lead to outbreaks in previously unaffected regions. This scenario necessitates the implementation of robust brucellosis control strategies, including stringent testing, monitoring, and vaccination programs. Governments and health organizations are compelled to invest in effective diagnostics and treatment solutions to mitigate the risks associated with this trade. Consequently, the demand for advanced brucellosis management tools and practices is expected to rise, promoting market growth.

Opportunities

• Integration of Telemedicine for Veterinary Care

The integration of telemedicine for veterinary care and remote diagnostic solutions represents a significant market opportunity in combating brucellosis, particularly in rural areas. By utilizing telemedicine, veterinarians can provide timely consultations, enabling farmers to address health concerns in livestock promptly without the need for extensive travel. Remote diagnostic technologies allow for quicker testing and analysis, facilitating early detection of brucellosis cases. This enhanced accessibility improves response times and empowers farmers with the necessary tools and knowledge to manage their herds effectively. As rural areas often face limitations in veterinary services, this integration can drive demand for innovative solutions, promoting overall market growth.

• Increasing Emphasis on Biosecurity

The increased emphasis on biosecurity in livestock farming presents a compelling market opportunity for brucellosis control products and services. As awareness of zoonotic diseases grows, farmers are prioritizing biosecurity measures to protect their herds from infections such as brucellosis. Implementing strict biosecurity protocols, such as controlling access to livestock, maintaining clean environments, and conducting regular health checks can significantly reduce the risk of disease transmission. This shift in focus creates a heightened demand for vaccines, diagnostic tools, and educational resources that support biosecurity efforts. Consequently, companies providing innovative solutions in biosecurity are well-positioned to capture a larger share of the brucellosis market, driving growth and improving overall herd health.

Restraints/Challenges

• Underreporting and Misdiagnosis

Many cases of brucellosis go unreported or misdiagnosed due to the disease's non-specific symptoms, such as fever, fatigue, and joint pain, which can mimic other common illnesses. This lack of clear differentiation results in an underestimation of its true prevalence, complicating public health efforts and hindering effective control measures. The limited awareness among healthcare professionals, especially in rural and resource-limited settings, further exacerbates this issue. As a consequence, without accurate data on infection rates, it becomes challenging to allocate resources effectively, implement targeted interventions, and develop strategies to educate communities, ultimately impeding progress in managing and controlling brucellosis outbreaks.

• High Cost of Effective Treatments and Diagnostics

The cost of effective treatments and diagnostics for brucellosis can be prohibitively high, presenting a significant restraint on market growth. Many healthcare systems, particularly in developing countries, struggle with limited budgets and resources, making it difficult to allocate funds for essential interventions. Farmers, especially those in low-income regions, may find it challenging to invest in costly diagnostic tests and treatments for their livestock. This financial burden can lead to delayed or inadequate responses to brucellosis outbreaks, hindering effective disease management. Consequently, the high costs associated with these interventions restrict access to vital resources, ultimately affecting public health outcomes and exacerbating the spread of the disease.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Brucellosis Market Scope

The market is segmented on the basis of treatment, transmission, route of administration, end-users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Medication
• Others

Transmission

• Raw Dairy Products
• Inhaling Contaminated Air
• Infected Blood & Body Fluids
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Brucellosis Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, treatment, transmission, route of administration, end-users, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the brucellosis market, attributed to its access to advanced technologies and significant investment in research and development. The region's high healthcare expenditure fosters innovation in diagnostics and treatments, enhancing disease management capabilities. This strong focus on technological advancement and R&D positions North America as a key player in the global brucellosis market.

Europe has experienced positive growth in the global brucellosis market, driven by an increase in animal husbandry and poultry farming. The region's robust agricultural sector, coupled with the presence of numerous generic manufacturers, has further supported this growth. This combination of factors has positioned Europe as a significant contributor to the overall expansion of the brucellosis market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Brucellosis Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Brucellosis Market Leaders Operating in the Market Are:

• Fresenius SE & Co. KGaA (Germany)
• Pfizer Inc (U.S.)
• Viatris Inc. (U.S.)
• Novartis AG (Switzerland)
• HIKMA PHARMACEUTICALS PLC (U.K.)
• Aurobindo Pharma (India)
• AbbVie Inc. (U.S.)
• Bayer AG (Germany)
• Colorado Serum Company (U.S.)
• Indian Immunologicals Ltd. (India)
• HESTER BIOSCIENCES LIMITED (India)
• JOVAC (Jordan)

Latest Developments in Brucellosis Market

• In March 2024, Boehringer Ingelheim, a prominent player in the animal health industry, partnered with Square Pharmaceuticals to introduce Aftovaxpur in Bangladesh. This innovative vaccine is designed to combat foot-and-mouth disease (FMD) in ruminants, such as cattle and sheep. The launch aims to improve livestock health and bolster the agricultural sector in the region
• In April 2023, scientists at Cornell University's College of Veterinary Medicine (CVM) developed a novel diagnostic test for identifying Brucella canis. This innovative test enables early diagnosis of the zoonotic disease, which can be transmitted to humans through contact with infected dogs. As a result, this advancement is expected to promote increased vaccination efforts over time
• In April 2022, Ceva Santé Animale and Mitsui & Co., Ltd. formed a joint venture to expand veterinary laboratory capabilities in Japan. This collaboration aims to tackle the challenges related to animal diseases and food safety within the country. As a result, this initiative is anticipated to significantly contribute to market growth by enhancing disease management and ensuring safer food production practices
• En septembre 2020, Hester Biosciences a annoncé un accord pour acquérir une technologie indigène de l'ICAR-IVRI (Indian Council of Agricultural Research - Indian Veterinary Research Institute) pour développer le vaccin Brucella Abortus S19 Delta Per. Cette décision stratégique a permis à l'entreprise d'élargir son portefeuille de produits et d'améliorer son offre sur le marché des vaccins vétérinaires. Par conséquent, elle devrait stimuler la génération de revenus et renforcer la position de Hester Biosciences dans l'industrie

SKU-53764